2025 Randomized Trial Tests Esketamine as a Standalone Depression Treatment

A randomized trial published online in JAMA Psychiatry on July 2, 2025, examined whether esketamine nasal spray could reduce depressive symptoms without an accompanying oral antidepressant in adults with treatment-resistant depression. The publication added peer-reviewed detail to a treatment approach included in Spravato’s expanded U.S. labeling earlier that year. Read the journal’s trial publication.

A direct test of monotherapy

The study was a phase 4, double-blind, placebo-controlled randomized clinical trial conducted at 51 U.S. outpatient centers from November 2020 through January 2024. It enrolled adults with major depressive disorder without psychotic features who had experienced inadequate responses to previous antidepressant treatment. The PubMed abstract describes the study design.

The clinical question was specific: could esketamine administered on its own improve depressive symptoms compared with placebo in this treatment-resistant population? That is different from asking whether esketamine should replace all other antidepressants or whether the same approach works across every depressive disorder.

Why the comparator matters

The trial reported an antidepressant benefit for esketamine monotherapy compared with placebo. Its primary assessment focused on depressive symptom change over the initial four-week treatment period. These findings support the standalone approach under the conditions studied. See the reported efficacy findings.

However, placebo is not the same comparator as an established medication strategy, electroconvulsive therapy, or Spravato plus an oral antidepressant. A positive placebo-controlled study does not by itself rank those alternatives or identify the best choice for a particular patient.

What the study population tells readers

Participants had treatment-resistant major depression without psychotic features. This eligibility framework matters when applying the findings. A trial in that population should not be presented as direct evidence for psychotic depression, every bipolar depressive episode, or a primary anxiety or trauma-related disorder. Review the eligibility description.

For readers assessing a treatment offer, the practical question is whether their diagnosis and treatment history resemble the population studied. A clinician may consider information beyond one trial, but that broader judgment should be distinguished from what this particular experiment tested.

Short-term efficacy is not every clinical question

A four-week controlled assessment is useful for evaluating initial symptom change. It is not, by itself, a complete account of how an individual will do over years, how long treatment should continue, or what should happen after a missed visit. Those are additional treatment-planning questions rather than automatic conclusions from a primary endpoint.

Likewise, a group-level benefit does not guarantee an individual response. Patients and clinicians still need a plan for evaluating change, tolerability, and whether ongoing treatment is justified. Asking about that plan is compatible with recognizing the trial’s positive result.

Industry involvement deserves disclosure

The publication’s disclosures identify multiple authors as Johnson & Johnson employees and stockholders. That information is relevant context because the company markets Spravato. Disclosure does not nullify the results, but it belongs alongside discussion of the randomized design, comparator, and limitations. Review the author affiliations and disclosures.

Readers should be able to separate the study’s reported data from promotional conclusions. The most useful summary states what was tested and found without extending the result to products or outcomes the trial did not examine.

The approval still includes safety conditions

Under the FDA’s January 2025 label, Spravato can be used alone or with an oral antidepressant for adult treatment-resistant depression. It still requires supervised administration and at least two hours of monitoring, with boxed warnings covering sedation, dissociation, respiratory depression, and abuse or misuse. Read the prescribing requirements.

The takeaway

The trial is important because it tests a clearly defined standalone esketamine strategy rather than assuming evidence from combination treatment automatically applies. Its positive result strengthens that specific evidence base. It does not settle every treatment comparison, remove safety requirements, or establish that compounded ketamine formulations produce the same outcomes.

For patients discussing the publication with a clinician, the central questions are whether the evidence fits their condition, which alternatives remain appropriate, and how a monitored treatment trial would be evaluated in their own care.

Sources

• JAMA Psychiatry: Esketamine monotherapy randomized clinical trial
• PubMed: Trial abstract and publication information
• FDA: Spravato prescribing information